This study is a randomized double-blind placebo-controlled multicenter clinical trial to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cell (UC-MSC) transplantation for the treatment of acute-on-chronic liver failure (ACLF). UC-MSC therapy may improve the clinical outcomes of patients with ACLF. The trial would provide scientific evidence for UC-MSC transplantation as a potential treatment for ACLF.
18 years old ≤ age ≤ 70 years old, gender is not limited.
Meet the APASL definition of ACLF: acute liver injury in patients with previously diagnosed or undiagnosed chronic liver disease or cirrhosis, manifested as jaundice (total bilirubin levels of 5 mg/dl or more) and coagulopathy (INR of 1.5 or more, or prothrombin activity of less than 40%） complicated within 4 weeks by clinical ascites, encephalopathy, or both.
Willing to sign the informed consent form.
Patients with acute kidney injury, upper gastrointestinal hemorrhage, hepatic encephalopathy above grade II (inclusive) or uncontrolled infection at baseline;
Before the onset of liver failure, the previous indicators of the patient included PLT<50×10^9/L or Child-Pugh score>9;
Combined with liver cancer or other malignant tumors;
Patients with previous liver transplantation or planned liver transplantation within 3 months;
Beijing 302 Hospital
Lead sponsor
Shulan (Hang Zhou) Hospital
Collaborator
BeijingYouan Hospital
Collaborator
Shenzhen Third People's Hospital
Collaborator
Shen Zhen Wingor Biotechnology CO. LTD
Collaborator